Healthy Skepticism Library item: 11014

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Metcalfe S, Evans J, Priest G.
PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
N Z Med J 2007 Jun 15; 120:(1256):U2593
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17589560&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Abstract:

A 9-week regimen of trastuzumab (Herceptin) given concurrently with a taxane will be funded for HER2-positive early breast cancer patients in New Zealand. The use of trastuzumab in this population has been investigated in sequential (after chemotherapy) or concurrent (with taxane chemotherapy) settings. Five RCTs have been reported—HERA, NSABP B31, NCCTG N9831, BCIRG 006, and FinHer. Uncertainty persists about optimal regimen duration, dose and sequencing, how to minimise cardiotoxicity, and long-term clinical outcomes. The evidence for the 9-week concurrent regimen was sufficient to justify funding. This regimen has shown results comparable to longer duration treatments; allows more patients to be treated; is relatively cost-effective; and DHBs have indicated they can provide sufficient ancillary support services. Longer duration regimens remain unfunded because of uncertainty surrounding long term clinical benefits and risks; the high cost; effects on DHB services; and their consequential unfavourable relative cost effectiveness. New data—from the sequential treatment arm of trial N9831, showing benefits that were small and statistically non-significant, and the HERA 23-month follow-up, suggesting a waning in efficacy with time—have since cast further doubt on the extent and durability of the sequential 12-month regimen’s efficacy. DHBs and PHARMAC remain open to funding longer duration regimens if cost effectiveness improves significantly and budget/resource implications become acceptable. PHARMAC has committed to international efforts (the SOLD trial) to resolve questions of optimal treatment duration.

Keywords:
Publication Types: Review MeSH Terms: Adult Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal/economics Antineoplastic Combined Chemotherapy Protocols/administration & dosage* Antineoplastic Combined Chemotherapy Protocols/economics Breast Neoplasms/drug therapy* Breast Neoplasms/genetics* Breast Neoplasms/mortality Bridged Compounds/administration & dosage Bridged Compounds/economics Chemotherapy, Adjuvant Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug Industry/economics* Female Financial Management Follow-Up Studies Genes, erbB-2* Humans Middle Aged New Zealand Proportional Hazards Models Randomized Controlled Trials Risk Assessment Survival Analysis Taxoids/administration & dosage Taxoids/economics Time Factors Substances: Antibodies, Monoclonal Bridged Compounds Taxoids trastuzumab taxane